X-GEN receives approval for drug

January 15, 2009

X-GEN Pharmaceuticals Inc. will begin marketing injectable acetazolamide for indications including open-angle glaucoma, secondary glaucoma, and preoperative use for the treatment of acute angle-closure glaucoma.

Key Points

Big Flats, NY-X-GEN Pharmaceuticals Inc. will begin marketing injectable acetazolamide for indications including open-angle glaucoma, secondary glaucoma, and preoperative use for the treatment of acute angle-closure glaucoma.

A commercially available brand is equivalent (Diamox, Duramed Pharmaceuticals), according to the company. Each vial contains acetazolamide sodium equivalent to 500 mg of acetazolamide in the form a sterile, preservative-free lyophilized powder.

"Currently, there is only one supplier of acetazolamide for injection USP," said Susan Badia, X-GEN president and chief executive officer. "Our launch of this product will ensure consistent supply and steady, competitive price levels."

Related Content:

News